Durvalumab

Programmed Death Ligand-1 Blocker — ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS

Key facts

Durvalumab is a drug in the Programmed Death Ligand-1 Blocker class catalogued in DrugCentral. It was first approved by the FDA in 2017. Its mechanism of action is classified as Programmed Death Ligand-1 Antagonists and Programmed Death Ligand-1-directed Antibody Interactions. DrugCentral lists 1 molecular target, including CD274. Recorded indications include Extensive stage primary small cell carcinoma of lung, Liver cell carcinoma, Metastatic carcinoma to biliary tract and Non-small cell lung cancer.

• Drug class: Programmed Death Ligand-1 Blocker.
• Mechanism of action: Programmed Death Ligand-1 Antagonists; Programmed Death Ligand-1-directed Antibody Interactions.
• Molecular targets: CD274 (1 listed in DrugCentral).
• Indications: Extensive stage primary small cell carcinoma of lung, Liver cell carcinoma, Metastatic carcinoma to biliary tract, Non-small cell lung cancer and Small cell carcinoma of lung and others.
• ATC code: L01FF03 (PD-1/PD-L1 (Programmed cell death protein 1/death ligand 1) inhibitors).

Indications & contraindications

Drug–disease relationships curated by DrugCentral (OMOP / SNOMED concepts).

Indications (6)

• Extensive stage primary small cell carcinoma of lung
• Liver cell carcinoma
• Metastatic carcinoma to biliary tract
• Non-small cell lung cancer
• Small cell carcinoma of lung
• Transitional cell carcinoma

Mechanism & targets

• Mechanism of action (MoA): Programmed Death Ligand-1 Antagonists; Programmed Death Ligand-1-directed Antibody Interactions
• Established pharmacologic class: Programmed Death Ligand-1 Blocker

Molecular targets (1)

Target	Gene	Action	Activity
Programmed cell death 1 ligand 1	CD274	other	—

Regulatory approvals (3)

Date	Agency	Marketed as	Applicant	Orphan
2018-09-21	EMA	—	ASTRAZENECA AB
2018-07-02	PMDA	—	AstraZeneca KK
2017-05-01	FDA	—	ASTRAZENECA UK LTD

ATC classification

ATC code	Therapeutic hierarchy
L01FF03	ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS › ANTINEOPLASTIC AGENTS › MONOCLONAL ANTIBODIES AND ANTIBODY DRUG CONJUGATES › PD-1/PD-L1 (Programmed cell death protein 1/death ligand 1) inhibitors

Pharmacogenomics

Drug-label and guideline annotations from PharmGKB and CPIC.

• EMA label: ALK, CD274, EGFR · Testing Required
• FDA label: ALK, CD274, EGFR, PDCD1 · Testing Required
• HCSC label: CD274

Reported adverse-event signals

Strongest FDA FAERS disproportionality signals (log-likelihood ratio). A signal is a statistical association in spontaneous reports, not proof that the drug causes the event.

MedDRA term	LLR
Radiation pneumonitis	3408.6
Malignant neoplasm progression	2476.7
Death	1875.5
Pneumonitis	1760.8
Interstitial lung disease	694.4
Immune-mediated enterocolitis	687.7
Metastases to central nervous system	605.0
Cholangitis	597.6
Neutrophil count decreased	584.2
Myocarditis	580.2
Colitis	567.1
Immune-mediated hepatic disorder	513.4

Chemical structure

• Molecular formula: —
• Molecular weight: —
• CAS number: 1428935-60-7
• InChIKey: —
• PubChem CID: —

Frequently asked questions

Answers are generated from the structured data on this page, not written by hand.

What is Durvalumab used for?

DrugCentral lists the following indications for Durvalumab: Extensive stage primary small cell carcinoma of lung, Liver cell carcinoma, Metastatic carcinoma to biliary tract, Non-small cell lung cancer, Small cell carcinoma of lung and Transitional cell carcinoma.

How does Durvalumab work?

Durvalumab is classified as Programmed Death Ligand-1 Antagonists and Programmed Death Ligand-1-directed Antibody Interactions; its molecular targets in DrugCentral include CD274.

When was Durvalumab first approved?

Durvalumab was first approved by the FDA in 2017.

What drug class does Durvalumab belong to?

Durvalumab is in the Programmed Death Ligand-1 Blocker class.

Sources

• DrugCentral drug card 5234 — structure, indications, targets, approvals, pharmacologic classes (CC BY-SA 4.0)
• ChEMBL CHEMBL3301587 — compound record and bioactivity
• DrugBank DB11714 — drug record
• FDA UNII 28X28X9OKV — substance identity
• DailyMed: FDA labels for Durvalumab — current prescribing information (label search)
• UniProt Q9NZQ7 (CD274) — target protein
• FDA Adverse Event Reporting System (openFDA FAERS) — adverse-event signals, as aggregated by DrugCentral
• PharmGKB / CPIC — pharmacogenomic label annotations

How this page is built: methodology · editorial policy & corrections.